<unk> , sold under the brand name Lupkynis, is a calcineurin inhibitor used as an immunosuppressant medication. It was approved by the U.S. Food and Drug Administration (FDA) for the treatment of lupus nephritis (LN) in January 2021. It is an analog of ciclosporin that has enhanced action against calcineurin and greater metabolic stability. Initially,<unk>  was a mixture of equal proporations of cis and trans geometric isomers of amino acid-1 modified cyclosporin. Later, in collaboration with Roche in Basel, Switzerland,<unk> 's manufacturing was changed to yield the predominantly trans isomer which possesses most of the beneficial effect of the drug (immunosuppression) in the treatment of organ transplantation and autoimmune diseases.
Voclosporin
Dapsone
Ciclosporin
Caspofungin
Cortistatin 
Ketoconazole
Miconazole
Itraconazole